JFA
HBIO icon

JNBA Financial Advisors’s Harvard Bioscience HBIO Stock Holding History

JNBA Financial Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed – – 631
2019
Q2 		$0 Buy
+10
New +$293 ﹤0.01% 683

Other funds holding HBIO

ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

JNBA Financial Advisors's HBIO Position: Q3 2019 in Review

JNBA Financial Advisors sold out of Harvard Bioscience (HBIO) in Q3 2019, closing a stake of 10 shares.

JNBA Financial Advisors first reported a position in HBIO in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 71 funds tracked by Wall St. Rank hold HBIO as of Q3 2019.

  • JNBA Financial Advisors reported no remaining Harvard Bioscience position as of Q3 2019 after selling out during the quarter.
  • JNBA Financial Advisors sold 10 Harvard Bioscience shares in Q3 2019.
  • JNBA Financial Advisors first reported a position in Harvard Bioscience in Q2 2019 and held it in 1 quarter.
  • JNBA Financial Advisors's Harvard Bioscience position peaked at $0 in Q2 2019.
  • 71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2019.

Based on JNBA Financial Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.